by Kelli Jones | Aug 2, 2018 | Latest News, Research
During pregnancy, the first cells that form the embryo must dull the maternal immune system to avoid being recognized as a foreign threat and be rejected. An aggressive form of breast cancer known as triple negative carcinoma uses a similar strategy, hijacking the...
by Garth Sundem | Jul 10, 2018 | Featured, Latest News, Research
Phase 1b clinical trial results published in JAMA Oncology show promise for the combination of tucatinib (formerly ONT-380) with T-DM1 against heavily pretreated HER2-positive breast cancer. Of 57 patients treated, 48 percent responded to the combination, with cancer...
by Erika Matich | Jun 13, 2018 | C3 Magazine, Featured
In 1974, First Lady Betty Ford went public with her breast cancer diagnosis and subsequent mastectomy, launching breast cancer into the national consciousness. Watergate was still fresh in everyone’s minds, and Mrs. Ford said that part of the reason she spoke so...
by Garth Sundem | May 14, 2018 | Featured, Latest News, Research
Therapies that recruit the immune system to attack tumors are revolutionizing cancer care. Among these successful immunotherapies is a class known as “checkpoint inhibitors” that unmask tumors’ ability to hide from the immune system. However, checkpoint inhibitors...
by Erika Matich | Jan 10, 2018 | Latest News, Patient Care, Research
Metastatic triple-positive breast cancer frequently resists treatments. Scientists at the University of Colorado Cancer Center are testing a unique combination of medications to change that. Growth of breast cancer cells is often propelled by one of three receptors –...
